Triglide is a drug owned by Skyepharma Ag. It is protected by 1 US drug patent filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Sep 11, 2021. Details of Triglide's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US6696084 | Spray drying process and compositions of fenofibrate |
Sep, 2021
(3 years ago) |
Expired
|
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Triglide's patents.
Latest Legal Activities on Triglide's Patents
Given below is the list of recent legal activities going on the following patents of Triglide.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| File Marked Found | 27 Aug, 2008 | US6696084 (Litigated) |
| Correspondence Address Change Critical | 20 Apr, 2004 | US6696084 (Litigated) |
| Patent Issue Date Used in PTA Calculation Critical | 24 Feb, 2004 | US6696084 (Litigated) |
| Recordation of Patent Grant Mailed Critical | 24 Feb, 2004 | US6696084 (Litigated) |
| Issue Notification Mailed Critical | 05 Feb, 2004 | US6696084 (Litigated) |
| Receipt into Pubs | 14 Jan, 2004 | US6696084 (Litigated) |
| Change in Power of Attorney (May Include Associate POA) Critical | 09 Jan, 2004 | US6696084 (Litigated) |
| Application Is Considered Ready for Issue Critical | 09 Jan, 2004 | US6696084 (Litigated) |
| Correspondence Address Change Critical | 09 Jan, 2004 | US6696084 (Litigated) |
| Receipt into Pubs | 29 Dec, 2003 | US6696084 (Litigated) |
US patents provide insights into the exclusivity only within the United States, but Triglide is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Triglide's family patents as well as insights into ongoing legal events on those patents.
Triglide's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Triglide's generic launch date based on the expiry of its last outstanding patent is estimated to be Sep 11, 2021 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Triglide Generic API suppliers:
Fenofibrate is the generic name for the brand Triglide. 34 different companies have already filed for the generic of Triglide, with Alembic having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Triglide's generic
Alternative Brands for Triglide
Triglide which is used for treating dyslipidemia and dyslipoproteinemia., has several other brand drugs using the same active ingredient (Fenofibrate). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | ||
|---|---|---|---|
| Abbvie |
| ||
| Cipher Pharms Inc |
| ||
| Lupin |
| ||
| Salix |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Fenofibrate, Triglide's active ingredient. Check the complete list of approved generic manufacturers for Triglide
About Triglide
Triglide is a drug owned by Skyepharma Ag. It is used for treating dyslipidemia and dyslipoproteinemia. Triglide uses Fenofibrate as an active ingredient. Triglide was launched by Skyepharma Ag in 2005.
Approval Date:
Triglide was approved by FDA for market use on 07 May, 2005.
Active Ingredient:
Triglide uses Fenofibrate as the active ingredient. Check out other Drugs and Companies using Fenofibrate ingredient
Treatment:
Triglide is used for treating dyslipidemia and dyslipoproteinemia.
Dosage:
Triglide is available in tablet form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 50MG | TABLET | Discontinued | ORAL |
| 160MG | TABLET | Prescription | ORAL |